Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameRecombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Drug Alias Namerecombinant SARS-CoV-2 vaccine (protein subunit/CHO cell) (Anhui Zhifei Longcom Biologic Pharmacy Co)COVID-19 vaccine (Anhui Zhifei Longcom Biologic Pharmacy Co)
ClassificationVaccines > Application > Prophylactic vaccineBiologics > Protein drugs > Recombinant proteinVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUzbekistanMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesAnhui Zhifei Longcom Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnhui Zhifei Longcom Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A